Investor Presentation Full Year 2021
88
Investor presentation Full year 2021
Two phase 3 trials were initiated in 2021 with oral semaglutide
14 mg in Alzheimer's Disease
Alzheimer's Disease
evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients
Novo NordiskⓇ
3 mg
7 mg
14 mg oral semaglutide QD
14 mg oral semaglutide QD
R
3 mg
7 mg
14 mg placebo QD
14 mg placebo QD
1:1
+
Week 0
4
104
Treatment period
↑
Confirmatory
endpoints
156
161
Follow-up
Large unmet need
within Alzheimer's
Disease with ~85 million
people living with mild
cognitive impairment
and dementia
Objective
To confirm superiority of
oral sema vs placebo on
the change in cognition
and function in people with
early Alzheimer's disease
Primary endpoint
Change in the Clinical
Dementia Rating - Sum
of Boxes (CDR-SB) score
from baseline to end of
104 weeks of treatment
•
Inclusion criteria
Early Alzheimer's Disease (mild cognitive impairment
or mild dementia)
Mini-Mental State Examination (MMSE) ≥ 22/30
•
Age between 55-85 years
•
evoke+ has at least 20% with small vessel pathology
Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460),
AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; Note: CDR-SB ratings are utilising in six domains are summed to provide a clinical measure = Sum of Boxes. These are: memory, orientation, judgment and problem solving,
community affairs, home and hobbies, personal care. CDR-SB Scores range from 0 to 18 with higher scores representing greater impairmentView entire presentation